Pharmaceutical Executive-09-01-2008

Features
Pharmaceutical Executive

September 01, 2008

Pharm Exec's 7th annual review of the top companies. We slice and dice the numbers to see who's the best a what. (pdf)

Toolkit
Pharmaceutical Executive

September 01, 2008

Effective January 1st, sales reps will have a new standard for dealing with doctors the PhRMA way

Pharmaceutical Executive
Features

September 01, 2008

FDAAA means that you need to register clinical trials-and not only for publication planning

Pharmaceutical Executive

Outsourcing saves money-except when it doesn't. Here's how to decide what to do.

Pharmaceutical Executive
Washington Report

September 01, 2008

FDA missteps and global outsourcing are drawing Congressional scrutiny and prompting new oversight approaches

Leadership
Pharmaceutical Executive

September 01, 2008

Leaders don't always manage to do the right thing, but they constantly strive to access the wellspring of integrity within them

Pharmaceutical Executive
Back Page

September 01, 2008

Young & Partners crunches pharma's filings for, the first half of '08. The results? Ask the Japanese

Pharmaceutical Executive
Columns

September 01, 2008

The smart way to CRM is through SaaS

Pharmaceutical Executive
From the Editor

September 01, 2008

The United States makes the best medicines in the world. In days to come, that could be a problem.

Pharmaceutical Executive
Features

September 01, 2008

Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital.

Pharmaceutical Executive
Features

September 01, 2008

The industry is a-changing. Here are eight seminal events that describe how.

Opinion
Pharmaceutical Executive

September 01, 2008

The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains

Pharmaceutical Executive

How will pharma fare in the new age of health and wellness marketing?

Global Report
Pharmaceutical Executive

September 01, 2008

In order to take a big step forward, GSK looks to employ smaller licensing deals and business units